Clinical trials: Pancreas Tumor
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Rectal Cancer, Pancreatic Cancer
Multimodal Imaging in Rectal Cancer & Pancreatic Cancer
Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years.
- Trial name
- MIRCA & MIPAC (NCT06395337)
- Testing
- [111In]In-DOTA-ANTI-CEA antibody injection, SPECT/CT scan, Resection surgery
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Pancreatic Cancer
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
It is hypothesized that OGF biotherapy may be safely administered in combination with gemcitabine to individuals with unresectable pancreatic cancer.
- Trial name
- NCT00783172
- Testing
- Gemcitabine, Opioid Growth Factor (OGF)
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Milton S. Hershey Medical Center
Pancreatic Cyst, Pancreatitis, Acute
Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts
The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered…
- Trial name
- NCT05572788
- Testing
- EUS-guided fine needle aspiration of pancreatic cysts
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Orlando Health, Inc.
Pancreatic Cancer
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally…
- Trial name
- NCT06313970
- Testing
- QL1706, Nab-paclitaxel, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma
Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
Pancreatic cancer has an extremely poor prognosis with a 5-year survival rate of less than 5%. About 25% of patients have the opportunity for radically surgical resection when diagnosis.
- Conditions
- Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma, Stage IIB Pancreatic Adenocarcinoma
- Trial name
- NCT02023021
- Testing
- nab-paclitaxel, gemcitabine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xian-Jun Yu
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle…
- Trial name
- NCT02562716
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride
- Where
- 807 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network
Pancreas Neoplasm, Stump
Routine Staple Line Reinforcement for Minimally Invasive Distal Pancreatectomy
Postoperative fistula is the major complications of distal pancreatectomies which prohibit patients' recovery. Previous studies have reported controversial results regarding the efficacy of pancreatic stump reinforcement methods.
- Conditions
- Pancreas Neoplasm, Stump, Surgery--Complications
- Trial name
- Double-Lock (NCT04663789)
- Testing
- reinforcement of the staple line, staple only
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Pancreatic Adenocarcinoma
A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
This is a phase 1b, multi-center, open label, randomized study to evaluate the safety and feasibility of administering metformin with or without rapamycin after disease stabilization on chemotherapy in subjects with metastatic…
- Trial name
- NCT02048384
- Testing
- metformin alone (Arm A), metformin (Arm B), rapamycin (Arm B)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Chronic Pancreatitis, Diabetes
Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
The data management systems, auditing, and monitoring effort are supported by the MD Anderson Cancer Center Clinical Research Support Center (CRSC).
- Conditions
- Chronic Pancreatitis, Diabetes, Pancreatic Cancer
- Trial name
- NCT03058926
- Testing
- Data Management and Monitoring
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- M.D. Anderson Cancer Center
Abdominal Cancer, Cancer Pain
Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous Approach
The goal of this prospective, interventional, non-randomized study was to compare pain score in unilateral and bilateral posterior percutaneous neurolytic celiac plexus block (NCPB) in upper abdominal cancer patients.
- Conditions
- Abdominal Cancer, Cancer Pain, Cancer of Pancreas
- Trial name
- NCT06316908
- Testing
- Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol, Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Sindh Institute of Urology and Transplantation
Advanced Pancreatic Cancer
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with with advanced pancreatic cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended…
- Trial name
- NCT04928625
- Testing
- SHR-A1904
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Postprocedural Gastric Stasis
Gastric Emptying After Infracolic or Supracolic Gastrojejunostomy Following Pancreaticoduodenectomy
Patients undergoing whipples pancreaticoduodenectomy tend to develop delayed gastric emptying. The study compares two types of anastamosis of stomach to jejunum (supracolic and infracolic) and compares whether it influences the…
- Trial name
- NCT01191138
- Testing
- Infracolic gastrojejunal anastamosis, Supracolic gastrojejunal anastamosis
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Asian Institute of Gastroenterology, India
Pancreatic Cancer, Pancreas Neoplasms
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States, and no combination therapy is far superior to gemcitabine alone.
- Trial name
- NCT00683085
- Testing
- HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
- Where
- Japan
- Volunteers
- 2 people
- Sponsor
- Tokyo University
Oncologic Complications, Quality of Life
Nutrition and Pharmacological Algorithm for Oncology Patients Study
Loss of appetite is a common symptom of patients with cancer and can cause distress which impacts patients and caregivers. Patients diagnosed with head/neck, lung or pancreatic cancer will be recruited for this study to decrease…
- Conditions
- Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer
- Trial name
- NCT04155008
- Testing
- Dexamethasone, Dronabinol, Mirtazapine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Metastatic Pancreatic Carcinoma
A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
This is a phase I clinical trial examining the safety, feasibility, and toxicity of gemcitabine and erlotinib when given in combination with capecitabine in adult patients with locally advanced unresectable or metastatic…
- Trial name
- NCT00480584
- Testing
- gemcitabine, capecitabine, erlotinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Biliary Tract Neoplasms, Gastric Cancer
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and…
- Conditions
- Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- VISIONARY (NCT04584008)
- Testing
- FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al., Other Therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Pancreatic Cancer
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells. Combining vaccine therapy with surgery may be an effective treatment for pancreatic cancer.
- Trial name
- NCT00003025
- Testing
- vitespen
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.